VIVEbiotech Marks World Cancer Day 2026
The company highlights its contribution to innovative oncology programs through lentiviral vector development and manufacturing.
February 4th marks World Cancer Day, a global initiative dedicated to raising awareness, inspiring action, and strengthening support for individuals and families affected by cancer.
At VIVEbiotech, we take this opportunity to recognize patients, caregivers, and the scientific and medical communities who work tirelessly to advance new cancer treatments and improve patient outcomes.
More than 60% of the lentiviral vectors we manufacture contribute to programs focused on developing innovative cancer therapies. We are proud to contribute our expertise and dedication to projects that drive progress in oncology and expand therapeutic options for patients worldwide.
To everyone facing this disease, to their loved ones, and to the professionals committed to scientific and clinical advancement, we extend our deepest respect, support, and appreciation.
Organizations seeking a reliable partner in lentiviral vector development and GMP manufacturing are invited to learn more about our capabilities or contact our team directly:
https://www.vivebiotech.com/en/contact/